Proteins perform a particularly diverse range of tasks in biological systems. To study how these molecules function in vitro and in vivo and to create new molecular entities with therapeutic and diagnostic capabilities, researchers have developed a broad range of methods to chemically modify proteins. While all of these methods are useful, they also all have disadvantages that limit their utility. Recently, we developed a method for enzymatically modifying proteins using the enzyme protein farnesyltransferase (PFTase). This method allows azide and alkyne-containing substrates to be transferred to proteins containing a small, four residue, and sequence at their C-terminus. Subsequent bio- orthogonal reaction of the azide or alkyne-functionalized protein can be used to prepare a wide variety of protein conjugates. What makes this approach unique is the fact that it allows selective covalent protein modification to be achieved with a minimalist tag. In this application we propose to capitalize on the utility of this protein modification strategy by applying it to several important problems in therapeutics while we continue to improve and refine it.
The specific aims of this project are: (1) Design and synthesize simplified azide-, alkyne-, and other functional group-containing substrates for PFTase (2) Develop a general directed evolution system to produce useful new mutants of PFTase including enzymes with relaxed and/or alternative isoprenoid and peptide/protein substrate specificity. (3) Use the PFTase catalyzed enzymatic protein modification method to prepare PEGylated forms of erythropoietin (EPO) and brain derived neurotrophic factor (BDNF) with increased stability and evaluate their neuroprotective efficacy following intranasal application in a rat hypoxia model. (4) Use a similar approach to prepare antibody-RNA conjugates that can be used to target siRNAs to T cells. If successful, the work described in this application could lead to improved protein- based drugs that could be used for the treatment of stroke, Alzheimer's and other neurodegenerative conditions as well as new, more selective agents for the treatment of autoimmune diseases and T cell leukemias. Moreover, the protein modification methodology developed here should be useful for the preparation of a wide variety of other protein conjugates that could be employed for a plethora of therapeutic and diagnostic applications.

Public Health Relevance

If successful, the work described in this application could lead to improved protein-based drugs that could be used for the treatment of stroke, Alzheimer's and other neurodegenerative conditions as well as autoimmune diseases and cancer. New methods will also be developed that could be translated into the development of novel therapeutic agents for other diseases as well.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM084152-03
Application #
8261103
Study Section
Macromolecular Structure and Function E Study Section (MSFE)
Program Officer
Edmonds, Charles G
Project Start
2010-05-01
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
3
Fiscal Year
2012
Total Cost
$272,064
Indirect Cost
$79,014
Name
University of Minnesota Twin Cities
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Mahmoodi, M Mohsen; Abate-Pella, Daniel; Pundsack, Tom J et al. (2016) Nitrodibenzofuran: A One- and Two-Photon Sensitive Protecting Group That Is Superior to Brominated Hydroxycoumarin for Thiol Caging in Peptides. J Am Chem Soc 138:5848-59
Palsuledesai, Charuta C; Ochocki, Joshua D; Kuhns, Michelle M et al. (2016) Metabolic Labeling with an Alkyne-modified Isoprenoid Analog Facilitates Imaging and Quantification of the Prenylome in Cells. ACS Chem Biol 11:2820-2828
Wang, Yen-Chih; Distefano, Mark D (2016) Synthetic isoprenoid analogues for the study of prenylated proteins: Fluorescent imaging and proteomic applications. Bioorg Chem 64:59-65
Mahmoodi, M Mohsen; Fisher, Stephanie A; Tam, Roger Y et al. (2016) 6-Bromo-7-hydroxy-3-methylcoumarin (mBhc) is an efficient multi-photon labile protecting group for thiol caging and three-dimensional chemical patterning. Org Biomol Chem 14:8289-300
Wickramaratne, Susith; Ji, Shaofei; Mukherjee, Shivam et al. (2016) Bypass of DNA-Protein Cross-links Conjugated to the 7-Deazaguanine Position of DNA by Translesion Synthesis Polymerases. J Biol Chem 291:23589-23603
Jennings, Benjamin C; Danowitz, Amy M; Wang, Yen-Chih et al. (2016) Analogs of farnesyl diphosphate alter CaaX substrate specificity and reactions rates of protein farnesyltransferase. Bioorg Med Chem Lett 26:1333-6
Dozier, Jonathan K; Distefano, Mark D (2015) Site-Specific PEGylation of Therapeutic Proteins. Int J Mol Sci 16:25831-64
Mahmoodi, Mohammad M; Rashidian, Mohammad; Zhang, Yi et al. (2015) Application of meta- and para-Phenylenediamine as Enhanced Oxime Ligation Catalysts for Protein Labeling, PEGylation, Immobilization, and Release. Curr Protoc Protein Sci 79:15.4.1-28
Diaz-Rodriguez, Veronica; Ganusova, Elena; Rappe, Todd M et al. (2015) Synthesis of Peptides Containing C-Terminal Esters Using Trityl Side-Chain Anchoring: Applications to the Synthesis of C-Terminal Ester Analogs of the Saccharomyces cerevisiae Mating Pheromone a-Factor. J Org Chem 80:11266-74
Zhang, Yi; Blanden, Melanie J; Sudheer, Ch et al. (2015) Simultaneous Site-Specific Dual Protein Labeling Using Protein Prenyltransferases. Bioconjug Chem 26:2542-53

Showing the most recent 10 out of 32 publications